Drugs / TRASTUZUMAB VEDOTIN
TRASTUZUMAB VEDOTIN
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04941339 | Nov 2018 → Oct 2022 | neoplasm | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05338957 | Aug 2022 → Jun 2024 | cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04492488 | May 2021 → Oct 2022 overdue | gastroesophageal cancer | Shanghai Miracogen Inc. | Active not recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06869174 | Mar 2025 → Mar 2027 expected | cancer of unknown primary site | Zhiguo Luo, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05263869 | Mar → Dec 2022 | breast cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05141747 | Jan 2022 → Dec 2023 | gastric cancer, gastroesophageal cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05141786 | Dec 2021 → Dec 2023 | non-small cell lung carcinoma | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04837508 | Jun 2021 → Dec 2022 | biliary tract cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04742153 | May 2021 → Feb 2023 | breast cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04839510 | Apr 2021 → Jun 2022 | urothelial carcinoma | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04924699 | Jun 2021 → Sep 2023 | breast cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05754853 Comparator | Apr 2023 → Oct 2025 overdue | urothelial carcinoma | Shanghai Miracogen Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRASTUZUMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315030 ↗ |
| Known as | MRG002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06869174 ↗ |
| Known as | Trastuzumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315030 ↗ |
| Known as | Trastuzumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315030 ↗ |
| Known as | Trastuzumab--vcmmae conjugate | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315030 ↗ |
| Route | Intravenous | “Administrated intravenously” NCT04492488 ↗ |